|Articles|January 12, 2015

Nivolumab Phase 3 Trial in NSCLC Stopped Early; Superior OS

Mid-trial evaluation by an independent Data Monitoring Committee found overall survival with Opdivo (nivolumab) in the Checkmate-017 trial was significantly better than the control arm. BMS now plans to submit results to the FDA for approval of the PD-1 inhibitor in lung cancer.

Opdivo

Bristol-Myers Squibb Company (NYSE:BMY) today announced that an open-label, randomized Phase 3 study evaluating versus docetaxel in previously treated patients with advanced, squamous cell non-small cell lung cancer was stopped early because an assessment conducted by the independent Data Monitoring Committee concluded that the study met its endpoint, demonstrating superior overall survival in patients receiving compared to the control arm. The company will share these data—which for the first time indicate a survival advantage with an anti-PD1 immune checkpoint inhibitor in lung cancer—with health authorities.

Complete press release by BMS: http://bit.ly/14NW37U

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!

Nivolumab Phase 3 Trial in NSCLC Stopped Early; Superior OS

Newsletter

Related Content

Abemaciclib Plus Endocrine Therapy Improves Overall Survival in High-Risk Early Breast Cancer

New Biomarkers, Drug Targets Identified for Colorectal Cancer

Manual Push Delivery of Rozanolixizumab for gMG Preferred by Patients

Altered Trace–Metal Homeostasis Linked to CKD Pathogenesis

Tryptophan Metabolism Linked to csDMARD Response in Rheumatoid Arthritis

Latest CME

From Strict Avoidance to Tailored Therapies: Transforming Food Allergy Care

The Evolving Strategies for Managing nAMD and DME: Empowering Managed Care Decisions for Improved Patient Outcomes

Managing Schizophrenia: Evidence-Based Care and Optimizing Value of New and Emerging Therapies

Closing Gaps in CLL Care: Managed Care Insights and Strategies

Revolutionizing Acute Pain Relief: Emerging Non-Opioid Therapies and the Essential Role of Pharmacists

Overview and Burden of Migraine

The Role of the Pharmacist Migraine Management

The Evolving Treatment Landscape of Migraine

Evidence-Based Guidelines Point to Leap in Care for Hypertrophic Cardiomyopathy

ASH Annual Meeting Coverage: Highlighting the Recent Updates in TKI Use in the Treatment of CML – Insights and Application for Managed Care

New and Approved: FDA’s 2024 Drug Lineup

Innovations in Medicine: 2024 Lineup of New and Approved Specialty Drugs

Revolutionizing Acute Pain Relief: Emerging Nonopioid Therapies and the Essential Role of Managed Care

Leveraging Managed Care to Optimize Patient Outcomes: Integrating Novel Treatments in Schizophrenia

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

Overcoming Operational and Clinical Barriers in Multiple Myeloma: Managed Care Strategies for Antibody-Based Regimens

Exploring Therapeutic Advances in Myelofibrosis and Key Considerations for Effective Management

Driving Better Outcomes in Hypertrophic Cardiomyopathy: A Managed Care Imperative

Optimizing the Uptake of Long-Acting Injectables in HIV Treatment and Prevention: Considerations for Managed Care

Harnessing Data-Driven Insights and Innovations to Enhance AMD and DME Management: Strategic Approaches for Managed Care

Navigating the Advancements in Oral Therapy Options in HR+ Metastatic Breast Cancer

Navigating the Changing Treatment Paradigm of Metabolic Dysfunction-Associated Steatohepatitis: A Guide for Managed Care Pharmacists

Managed Care Approaches and Models for Equitable Access to Innovations in Major Depressive Disorder Treatment

Evaluating the Effectiveness and Value of Novel Nonhormonal Treatments in the Management of Menopause-Related Vasomotor Symptoms

Updated Guidance and Managed Care Strategies to Optimize Respiratory Syncytial Virus Vaccination Coverage

Leveraging Biologics and Immunotherapies in the Management of Food Allergies

Advancing Care in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: Optimizing Outcomes With Emerging Therapies

The Evolving Landscape of Transthyretin Amyloidosis Cardiomyopathy: New Therapies and Treatment Strategies

Reflecting on the Real-World Use of Biologic Therapy in Asthma Management

Advancing Cystic Fibrosis Management: The Evolving Role of Specialty and Managed Care Pharmacists

Pulmonary Arterial Hypertension: Real-World Applications of New Therapies and Management Strategies

Targeting Chronic Rhinosinusitis With Nasal Polyps With Biologics: Optimizing Outcomes and Reducing Health Care Burden

Emerging Treatment Options for Inflammatory Bowel Disease: A Focus on IL-23 Pathway Inhibition

Transforming Metabolic Dysfunction-Associated Steatohepatitis Management: Pharmacist Considerations for the Evolving Treatment Landscape

Innovations in Inflammatory Bowel Disease Therapy: How IL-23 Inhibitors Are Shaping Treatment and Managed Care Approaches

The Expanding Therapeutic Landscape in IgA Nephropathy: Applying Evidence-Based Strategies and Guideline Updates for Managed Care

Leveraging Novel Therapies to Transform Demodex Blepharitis Care (Pharmacy Technician Credit)

Leveraging Novel Therapies to Transform Demodex Blepharitis Care

The Changing Paradigm in Pain Management and Supporting Access to Novel Therapies

The Expanding Therapeutic Landscape in IgA Nephropathy: A Case-Based Exploration of Optimized Patient Outcomes

Opioids, Pain Management, and Substance Use Disorder: A Practical Overview

Trending on AJMC

Medicare State Rankings Reveal Stark Differences in Access, Quality, and Affordability

Abemaciclib Plus Endocrine Therapy Improves Overall Survival in High-Risk Early Breast Cancer

New Biomarkers, Drug Targets Identified for Colorectal Cancer

Real-World Data Show Preventive Nirsevimab Reduces Infant RSV Hospitalizations

First-Line Zongertinib Yields Strong Responses in Patients With Advanced HER2-Mutant NSCLC